Literature DB >> 19028737

Novel optometrist-led all Wales primary eye-care services: evaluation of a prospective case series.

N J L Sheen1, D Fone, C J Phillips, J M Sparrow, J S Pointer, J M Wild.   

Abstract

AIMS: To derive an evidence base for the efficacy of two novel optometric primary eye care services in Wales, the Primary Eyecare Acute Referral Scheme (PEARS) and the Welsh Eye Health Examination (WEHE).
METHODS: A Donabedian model using structure, process and outcome was applied to evaluate prospectively 6432 individuals attending 274 optometrists within an 8-month period. Telephone interviews and review of optometric and hospital notes were used to determine management appropriateness for patients either managed in optometric practice or referred to the Hospital Eye Service (HES). A Geographic Information Systems analysis determined distances travelled to the optometrist. A cost analysis was used to determine the net cost of the schemes.
RESULTS: 4243 (66%) of the 6432 individuals were managed in optometric practice; inappropriate management was apparent in 1% of individuals. 392 hospital notes were reviewed; 75% exhibited appropriate optometric referrals to the HES. 87% of individuals travelled less than 5 miles to attend an optometrist. The net cost of a PEARS/WEHE consultation was a minimum of pound12.
CONCLUSIONS: Optometric management within the schemes is acceptable. Good equity of access was achieved at a relatively low net cost per consultation. Agreement on protocols for referral to the HES would enhance the schemes.

Entities:  

Mesh:

Year:  2008        PMID: 19028737     DOI: 10.1136/bjo.2008.144329

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  The urgent need to develop emergency EYE care in the UK: the way forward?

Authors:  J C Buchan; B Barnes; A Cassels-Brown; B Y Chang; J Harcourt; R F Pilling; D Shickle; A F Spencer; S A Vernon; C MacEwen
Journal:  Eye (Lond)       Date:  2017-06-16       Impact factor: 3.775

2.  Clinical "case series": a concept analysis.

Authors:  F M Abu-Zidan; A K Abbas; A F Hefny
Journal:  Afr Health Sci       Date:  2012-12       Impact factor: 0.927

Review 3.  Urgent Eye Care in the UK Increased Demand and Challenges for the Future.

Authors:  Thomas Siempis
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2014

4.  Multi-stakeholder perspectives of locally commissioned enhanced optometric services.

Authors:  H Baker; R A Harper; D F Edgar; J G Lawrenson
Journal:  BMJ Open       Date:  2016-10-25       Impact factor: 2.692

5.  Clinical safety of a minor eye conditions scheme in England delivered by community optometrists.

Authors:  Evgenia Konstantakopoulou; Robert A Harper; David F Edgar; Genevieve Larkin; Sarah Janikoun; John G Lawrenson
Journal:  BMJ Open Ophthalmol       Date:  2018-02-20

6.  A prospective evaluation of the clinical safety and effectiveness of a COVID-19 Urgent Eyecare Service across five areas in England.

Authors:  Alexander G Swystun; Christopher J Davey
Journal:  Ophthalmic Physiol Opt       Date:  2021-11-10       Impact factor: 3.117

7.  Optometry independent prescribing during COVID lockdown in Wales.

Authors:  Paul Cottrell; Rachel North; Nik Sheen; Barbara Ryan
Journal:  Ophthalmic Physiol Opt       Date:  2022-08-12       Impact factor: 3.992

8.  A qualitative study of stakeholder views regarding participation in locally commissioned enhanced optometric services.

Authors:  E Konstantakopoulou; R A Harper; D F Edgar; J G Lawrenson
Journal:  BMJ Open       Date:  2014-05-29       Impact factor: 2.692

9.  Demographics, referral patterns and management of patients accessing the Welsh Eye Care Service.

Authors:  Colm McAlinden; Helen Corson; Nik Sheen; Peter Garwood
Journal:  Eye Vis (Lond)       Date:  2016-05-18

10.  Evaluation of a minor eye conditions scheme delivered by community optometrists.

Authors:  E Konstantakopoulou; D F Edgar; R A Harper; H Baker; M Sutton; S Janikoun; G Larkin; J G Lawrenson
Journal:  BMJ Open       Date:  2016-08-10       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.